Table 4 List of microRNA (miRNA) expression is dysregulation in ALCL
From: Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Subtype of PTCL | Dysregulate microRNA | Biology significance |
|---|---|---|
PTCL-NOS | Overexpressed miR-187 [173] | (1) Associates with high Ki-67 expression, promotes T-lymphoma cell proliferation (2) Relates to tumour progression (3) MiR187 stabilized MYC oncoprotein through Ras-mediated ERK and AKT activation |
ALK + ALCL [174] | miR-17 ~ 92 overexpressed miR-135b | (1) Target BIM, identified to have a role in oncogenic ALK signalling in ALCLs (2) Sustain oncogenic properties of STAT3 in T-cell lymphoma [175] |
ALK − ALCL | miR-155 | expressed more than10-fold higher in ALK − ALCL. [174] |
ALCL [176] | Upregulation of miR-135b | (1) miR-135b mediates NPM-ALK–driven oncogenicity, targets GATA3, STAT6, FOXO1 (2) Renders IL-17-producing immunophenotype to anaplastic large-cell lymphoma |
ALK + ALCL | miR-16, MiR-29a, miR-96 Downregulation | (1) miR-16 regulate VEGF [177] downregulated (2) MiR-29a inhibiting apoptosis through overexpression of MCL-1 [146] (3) miR-96 a posttranscriptional suppressor, target ALK [178] |
ALK( +) ALCL | 5 upregulated: 2downregulated miR-155 miR-146a, | (1) miR-17 ~ 92 is an important downstream effector of ALK oncogenic pathway[179] |
ALK(−) ALCL | 4 Upregulated: 7 Downregulated: | (1) The signature of a series of 11 miRNAs distinguishes ALK (−) ALCL from other PTCLs. (2) Classification of peripheral T-cell lymphoma subtypes [179, 180] |
ALCL | miR-101 was downregulated in all ALCL cell lines, | (2) miR-101 in the regulation of mTOR pathway [174] |
AITL PTCL-NOS | BCL6 and a specific set of miRNAs | Mutual regulation between BCL6 and a specific set of miRNAs controls the TFH phenotype in peripheral T-cell lymphoma [181] |
Peripheral T-cell lymphoma not otherwise specified | Expression levels of miRNA | (1) Discriminating PTCL NOS from activated CD4 + and CD8 + T-lymphocytes, such as AITL and ALCL (2) miR-132-3p is also an important modulator of the PTCL NOS transcriptome [182] |
PTCL NOS | 13 miRNAs upregulated and 7 miRNAs downregulated | the potential to be used as biomarkers for the identification of patients with PTCL NOS [183] |
Angioimmunoblastic T-cell lymphoma. In AITL, | Upregulated: miR-146a, miR-193b miR-34a downregulated miR-30b | Both miR146-a and miR-30b contribute to the pathogenesis of AITL [184] |
ALK( +) ALCL | miR-21 Downregulated | Targets DNMT1 mRNA [103] |